InsiderTrades

Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-03 · accession 0001193125-26-093916 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-03-05 2026-03-03 TEVA Francis Richard D Pres, CEO S - Sale+OE $32.36 -442.9K 1.12M -28% -$14.33M
DMT 2026-03-05 2026-03-03 TEVA Francis Richard D Pres, CEO M - OptEx — +958.5K 673.0K New —
DMT 2026-03-05 2026-03-03 TEVA Francis Richard D Pres, CEO M - OptEx $0.00 -958.5K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2026-03-03 S D 30,903 $32.36 642,099 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
2 Common Ordinary Shares 2026-03-03 M A 891,315 — 1,533,414 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3 Common Ordinary Shares 2026-03-03 S D 412,032 $32.36 1,121,382 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
4 Common Ordinary Shares 2026-03-03 M A 67,231 — 673,002 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
5 Derivative Restricted Share Units 2026-03-03 M D 67,231 $0.00 67,231 D — · — to — 67,231 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F6) Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027.
6 Derivative Restricted Share Units 2026-03-03 M D 891,315 $0.00 0 D — · — to — 891,315 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F7) Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.